A Phase I Trial to Examine the Safety, Clinical, Immunologic and Virologic Effects of CMV pp65 Specific Cytotoxic T Lymphocytes for Recipients of Allogeneic Stem Cell Transplants With Persistent or Therapy Refractory Infections.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Cytomegalovirus vaccine vCP260 (Primary)
- Indications Cytomegalovirus infections
- Focus Adverse reactions; Biomarker; Therapeutic Use
- 09 May 2017 Biomarkers information updated
- 10 Jun 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 23 Aug 2007 New trial record.